Ebselen a safe lithium mimetic for bipolar disorder - an article from the Churchill and Sharp groups
In this article based on funding from the BBSRC we present evidence that ebselen works like lithium in mouse models of bipolar disorder. Both ebselen and lithium inhibit the same key signalling pathway to quiet overactive neurones. As ebselen has been in late stage clinical trials (Phase 3) for stroke, it has clinical safety and few side effects. Taking a known drug and using it for a new disease is termed repurposing and can dramatically reduce the time and cost of drug development. For ebselen, this means testing in man will occur within the next year by the lead author, Nisha Singh in collaboration with Professor Phil Cowen in Psychiatry.

Oxford Press Release: New drug for bipolar disorder may offer fewer side effects - University of Oxford
The article: http://www.nature.com/ncomms/journal...comms2320.html